On May 21, 2019 EXUMA Biotechnology and affiliate Shanghai PerHum Therapeutics reported interim results of two first-in-human solid tumor CAR-T products in subjects with recurrent or refractory stage IV metastatic renal cell carcinoma (mRCC) (Press release, EXUMA Biotechnology, MAY 21, 2019, View Source [SID1234536509]). The data, presented at the Association for Cancer Immunotherapy (CIMT) (Free CIMT Whitepaper) 2019 Annual Meeting, continues to support the feasibility, comparative safety and pharmacokinetics of dose escalation of two CAR-T products, CCT301-38 (AXL) and CCT301-59 (ROR2), in a single patient population.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The umbrella clinical trial design being run at SPHCC (Shanghai Public Health Clinical Center) under the direction of lead investigator Tongyu Zhu, M.D., examines the first two CAR-T products in human clinical trial to use AND logic gate control technology. The logic gate design leverages the tumor microenvironment (TME) – turning the growth inhibitory acidic TME into an activating signal – thereby minimizing the potential of on-target, off-tumor activity. One trigger of the logic gate is the TME, and the other is the target antigen (AXL or ROR2, depending on the product). Some of the key highlights presented include:
No dose-limiting toxicities have been observed to date with no indications of on-target, off-tumor toxicity attributed to either product.
CAR-T product blood exposure up to 80,000 copies/ μg observed at the 1 x 106/kg dose level.
Early radiologic evidence of antitumor activity, with stable disease as best response.
In this heavily pre-treated patient population, 6 out of 7 subjects are alive with a median follow-up of 140 days.
These interim results continue to support the potential of the company’s conditionally active biologics (CAB)-CAR-T technology to increase the safety profile of CAR-T therapeutics in mRCC and potentially other target-positive solid tumors.
"The cell processing feasibility, cell exposure and preliminary comparative safety of the two novel products support the potential of CAB-CAR-T technology for solid tumors," said Wendy Li, M.D., Chief Medical Officer of EXUMA Biotechnology. "We look forward to the complete data set from these ongoing clinical studies with collaborators and to bringing these programs forward into multicenter studies in the future."
The full abstract is now available on the annual CIMT (Free CIMT Whitepaper) meeting website (Abstract #123) and the poster will be presented on May 21, 9:00-11:30 am EST.